

- **Name:** **Jee Hyun Kim**  
**Professor, Division of Hematology & Medical Oncology,  
Department of Internal Medicine, Seoul National  
University Bundang Hospital, Seoul National University  
College of Medicine**
  - **Current Position & Affiliation:** **Director, Precision Medicine Center,  
Seoul National University Bundang Hospital**
  - **Country:** **Korea**
- 

- **Educational Background:**

- 2002 – 2004 Ph.D. in Internal Medicine, Seoul National University, Graduate School, Republic of Korea
- 2000 – 2002 M.S. in Internal Medicine, Seoul National University, Graduate School, Republic of Korea
- 1989 – 1995 M.D. degree from Seoul National University College of Medicine, Republic of Korea

- **Professional Experience:**

- 2019 – current: Director, Precision Medicine Center, Seoul National University Bundang Hospital
- 2017-2020: Director, Clinical trial center, Seoul National University Bundang Hospital
- 2015- current Professor, Seoul National University College of Medicine, Seoul National University Bundang Hospital
- 2011 – 2016: Chief, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital
- 2009-2015: Associate Professor, Seoul National University College of Medicine, Seoul National University Bundang Hospital
- 2008-2009 : Visiting professor, Division of molecular and cellular oncology, Department of Medical Oncology, Dana Farber Cancer Institute, U.S
- 2005-2008 : Assistant Professor, Seoul National University College of Medicine,
- 2003-2008: Assistant Professor, Seoul National University Bundang Hospital, Republic of Korea

- **Professional Organizations:**

- Director, Planning Committee, Korean Cancer Study Group (KCSG)
- Leader, Precision Medicine Networking Group, Korean Society of Medical Oncology (KSMO)
- Membership  
Korean Cancer Association (KCA)  
American Society of Clinical Oncology (ASCO)

American Association for Cancer Research (AACR)  
International Society of Geriatric Oncology (SIOG)

• **Main Scientific Publications:**

1. Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, Ko YH, Shin SH, Woo IS, Kim TY, Baek JY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Ryoo HM, Kim JH. Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. *Oncologist*. 2020 Mar;25(3):e502-e511. doi: 10.1634/theoncologist.2019-0085
2. Kim SH, Kim JW, Hwang IG, Jang JS, Hong S, Kim TY, Baek JY, Shin SH, Sun S, Hong DS, Kim HJ, Hong YS, Woo IS, Lee JH, Kim JH. Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. *J Geriatr Oncol*. 2019 Sep;10(5):749-756.
3. Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, Ko YH, Shin SH, Woo IS, Hong S, Kim TY, Baek JY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Ryoo HM, Lee KH, Kim JH. Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. *Cancer Res Treat*. 2019 Jul;51(3):1249-1256.
4. Lee YG, Lee JH, Kim SH, Kim YJ, Lee H, Ahn S, Jang JS, Lee JS, Kim JH. Comparative analysis between combination and single-agent chemotherapy. *Lung Cancer* 2018;122:88-93.
5. Kim JW, Lee YG, Hwang IG, Song HS, Koh SJ, Ko YH, Shin SH, Woo IS, Hong S, Kim TY, Kim SY, Nam BH, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Bae SH, Koo DH, Kim KI, Kim JH. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. *Br J Cancer*. 2018 May;118(9):1169-1175
6. Kim JW, Lee KW, Kim KP, Lee JH, Hong YS, Kim JE, Kim SY, Park SR, Nam BH, Cho SH, Chung IJ, Park YS, Oh HS, Lee MA, Kang HJ, Park YI, Song EK, Han HS, Lee KT, Shin DB, Kang JH, Zang DY, Kim JH, Kim TW. Efficacy and safety of FOLFIRI regimen in elderly versus nonelderly patients with metastatic colorectal or gastric cancer. *Oncologist* 2017;22:293-303.
7. Suh KJ, Kim SH, Lee KH, Kim TY, Kim YJ, Han SW, Kang E, Kim EK, Kim K, No JH, Han W, Noh DY, Lee M, Kim HS, Im SA, Kim JH. Bilateral Salpingo-Oophorectomy compared to gonadotropin-releasing hormone agonists in premenopausal hormone receptor-positive metastatic breast cancer patients treated with aromatase inhibitors. *Cancer Res Treat*. 2017;49:153-63.